StoneX Group Inc. bought a new position in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 107,083 shares of the medical instruments supplier's stock, valued at approximately $981,000. StoneX Group Inc. owned approximately 0.26% of AngioDynamics at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Arrowstreet Capital Limited Partnership lifted its holdings in AngioDynamics by 293.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 352,544 shares of the medical instruments supplier's stock valued at $3,229,000 after purchasing an additional 263,034 shares during the last quarter. Orion Portfolio Solutions LLC increased its holdings in shares of AngioDynamics by 7.4% during the fourth quarter. Orion Portfolio Solutions LLC now owns 179,897 shares of the medical instruments supplier's stock worth $1,648,000 after buying an additional 12,383 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of AngioDynamics by 46.0% in the 4th quarter. JPMorgan Chase & Co. now owns 807,483 shares of the medical instruments supplier's stock worth $7,397,000 after acquiring an additional 254,322 shares in the last quarter. Segall Bryant & Hamill LLC grew its position in AngioDynamics by 55.3% during the 4th quarter. Segall Bryant & Hamill LLC now owns 1,415,156 shares of the medical instruments supplier's stock worth $12,963,000 after acquiring an additional 503,713 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in AngioDynamics by 22.1% during the 4th quarter. American Century Companies Inc. now owns 67,942 shares of the medical instruments supplier's stock valued at $622,000 after purchasing an additional 12,306 shares in the last quarter. Institutional investors own 89.43% of the company's stock.
AngioDynamics Stock Performance
Shares of NASDAQ ANGO traded down $0.71 during trading on Friday, reaching $9.11. The company had a trading volume of 1,081,815 shares, compared to its average volume of 572,579. AngioDynamics, Inc. has a 52 week low of $5.47 and a 52 week high of $13.50. The business's 50 day moving average price is $10.16 and its 200-day moving average price is $8.88. The stock has a market cap of $368.65 million, a PE ratio of -1.62 and a beta of 0.52.
AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.16. The firm had revenue of $72.00 million during the quarter, compared to analysts' expectations of $70.30 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company's revenue for the quarter was down 4.3% compared to the same quarter last year. Equities analysts anticipate that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.
Analyst Upgrades and Downgrades
Separately, HC Wainwright boosted their price objective on AngioDynamics from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday, January 10th.
Check Out Our Latest Stock Report on ANGO
Insider Activity at AngioDynamics
In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the company's stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the transaction, the senior vice president now directly owns 41,817 shares in the company, valued at approximately $514,767.27. This represents a 8.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 5.40% of the stock is owned by company insiders.
About AngioDynamics
(
Free Report)
AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.
See Also
Before you consider AngioDynamics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AngioDynamics wasn't on the list.
While AngioDynamics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
